InsidersTradesSigma
Total declarations
Companies
▲ Purchases (63 ops.)
▼ Sales (31 ops.)
Insider track record
CEODisclosed buys
63
Disclosed sells
31
T+90 hit rate
20%
T+90 mean return
+66.2%
Across 20 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by PERCEPTIVE ADVISORS LLC, Managing Member / Founder and CEO. Insider active across 24 companies, notably Aldeyra Therapeutics, Inc.. Cumulatively, 105 reports have been published. Breakdown: 63 buys · 31 sells. Total volume traded: €461.6m. Activity tracked since 3 May 2021. The latest transaction was disclosed on 23 December 2025 (Attribution). Regulator: SEC (Form 4). The full history is free.
Declarations105 total
989,270 shares@ US$6.3567.1% of flowCommon StockSEC:0001012975-25-000979:0
329,756 shares@ US$6.3522.4% of flowCommon StockSEC:0001012975-25-000979:1
437,881 shares@ US$1.412.5% of flowCommon StockSEC:0001062993-25-008341:0
1,054,669 shares@ US$1.958.4% of flowCommon StockSEC:0001062993-25-008214:0
215,283 shares@ US$1.561.4% of flowCommon StockSEC:0001062993-25-008214:1
250,000 shares@ US$1.411.4% of flowCommon StockSEC:0001062993-25-008214:2
3,400,000 shares@ US$1.4210.5% of flowCommon StockSEC:0001062993-25-007163:0
5,000,000 shares@ US$4.0337.8% of flowCommon StockSEC:0001062993-25-003153:0
Ideal exit: 16 Nov 2025 (T+270)
64,167 sharesCommon StockSEC:0001062993-25-002547:0
1,250,000 shares@ US$4.0016.8% of flowOrdinary SharesSEC:0001062993-24-015109:0
Ideal exit: 9 May 2025 (T+270)
2,353,000 shares@ US$8.5086.3% of flowCommon StockSEC:0001062993-24-008378:0
Ideal exit: 6 Jan 2025 (T+270)
140,281 shares@ US$4.671.4% of flowCommon StockSEC:0001062993-24-008171:0
Ideal exit: 30 Dec 2024 (T+270)
8,374 shares@ US$3.250.1% of flowCommon StockSEC:0001062993-24-007959:0
Ideal exit: 27 Dec 2024 (T+270)
170,317 shares0Common StockSEC:0001062993-24-003957:0
36,300 shares@ US$2.520.1% of flowOrdinary SharesSEC:0001062993-24-003732:0
2,481,350 shares@ US$12.0961.4% of flowCommon StockSEC:0001062993-24-001979:0
Ideal exit: 28 Oct 2024 (T+270)
3,410,713 shares@ US$5.5333.7% of flowCommon StockSEC:0001062993-24-000843:0
Ideal exit: 7 Oct 2024 (T+270)
32,134 shares@ US$2.280.8% of flowCommon StockSEC:0001062993-23-023291:0
Ideal exit: 22 Sept 2024 (T+270)
79,726 shares@ US$7.207.1% of flowCommon StockSEC:0001062993-23-023292:0
Ideal exit: 22 Sept 2024 (T+270)
200,000 shares@ US$6.1715.5% of flowCommon StockSEC:0000899243-23-020691:0
Ideal exit: 16 Sept 2024 (T+270)
740,000 shares@ US$6.209.3% of flowCommon StockSEC:0001062993-23-023077:0
Ideal exit: 16 Sept 2024 (T+270)
500,000 shares@ US$5.9737.3% of flowCommon StockSEC:0001062993-23-022861:0
Ideal exit: 10 Sept 2024 (T+270)
2,579,502 sharesCommon StockSEC:0001062993-23-020811:0
614,062 shares@ US$6.5148.4% of flowCommon StockSEC:0001062993-23-019533:0
Ideal exit: 12 Jul 2024 (T+270)
2,450,000 shares@ US$1.608.9% of flowCommon StockSEC:0001062993-23-019546:0
25 of 105 declarations
About PERCEPTIVE ADVISORS LLC
Perceptive Advisors LLC is a life-sciences-focused investment firm founded in 1999. Its founder, Joseph Edelman, serves as the firm’s managing member, and SEC filings consistently identify him as the person controlling and representing the advisor in its investment vehicles. Perceptive’s own materials also describe Edelman as Chief Executive Officer & Portfolio Manager, underscoring his leadership across the firm’s healthcare investing activities. ([perceptivelife.com](https://www.perceptivelife.com/about?utm_source=openai))
